Yazarlar : Kindler T, Lipka DB, Fischer T.

Yayın : Blood

Yayın Yılı : 2010

Pubmed Linki : http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=2070

Konu : Lösemi

Literatür İçeriği :  Abstract

Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene on chromosome 13q12 have been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of the most frequently identified genetic alterations in AML. Over the last years, FLT3 has emerged as a promising molecular target in therapy of AML. Here, we review results of clinical trials and of correlative laboratory studies using small molecule FLT3 tyrosine kinase inhibitors (TKI) in AML patients. We also review mechanisms of primary and secondary drug resistance to FLT3-TKI and from the data currently available we summarize lessons learned from FLT3-TKI monotherapy. Finally, for using FLT3 as a molecular target we discuss novel strategies to overcome treatment failure and to improve FLT3 inhibitor therapy.

Literatür Arşivi